Joint Formulary & PAD

Dupilumab - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :

No records returned.

Associated Icons :
Restrictions / Comments :
Important

Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.

This drug has not yet been assessed for formulary status for COPD.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug (publication date to be confirmed) and this will be considered by the APC within 90 days of publication.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Dupilumab
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
0

Other Indications

Below are listed other indications that Dupilumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (0)

  • No records returned.